Poolbeg Pharma "really open" to different types of deal for POLB 001

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) VP of Business Development David English speaks to Proactive's Thomas Warner about the work he's doing to progress the clinical stage infectious disease pharmaceutical company's lead asset POLB 001.

English says that Poolbeg is "in a good position" for partnering in general, adding that the company is "really open" to different types of deals for lead asset POLB 001.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  257.37
+0.00 (0.00%)
AAPL  349.21
+0.00 (0.00%)
AMD  489.19
+0.00 (0.00%)
BAC  48.57
+0.00 (0.00%)
GOOG  271.02
+0.00 (0.00%)
META  596.22
+0.00 (0.00%)
MSFT  498.30
+0.00 (0.00%)
NVDA  145.98
+0.00 (0.00%)
ORCL  110.57
+0.00 (0.00%)
TSLA  374.41
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.